NCT01299012

Brief Summary

Evaluating the use of Liraglutide in patients with Type 1 Diabetes.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2010

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 1, 2011

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 18, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2013

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

February 9, 2017

Status Verified

February 1, 2017

Enrollment Period

2.3 years

First QC Date

February 1, 2011

Last Update Submit

February 8, 2017

Conditions

Type 1 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

  • Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide

    20 weeks

Interventions

LiraglutideDRUG

Liraglutide s/c 0.6mg once daily.

Also known as: Victoza

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Type 1 Diabetes Mellitus

You may qualify if:

  • Type 1 Diabetes Mellitus

You may not qualify if:

  • Type 2 Diabetes Mellitus

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

Liraglutide

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Glucagon-Like Peptide 1Glucagon-Like PeptidesProglucagonGastrointestinal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Paresh Dandona

    University at Buffalo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

February 1, 2011

First Posted

February 18, 2011

Study Start

October 1, 2010

Primary Completion

February 1, 2013

Study Completion

June 1, 2013

Last Updated

February 9, 2017

Record last verified: 2017-02